Related Experiment Videos
Integrin beta4 signaling promotes tumor angiogenesis
Sotiris N Nikolopoulos1, Pamela Blaikie, Toshiaki Yoshioka
1Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Cancer Cell
|November 16, 2004
Summary
Integrin alpha6beta4 signaling is crucial for pathological angiogenesis, promoting vessel branching, migration, and invasion. Blocking this pathway in mice significantly reduced tumor vascularization, identifying it as a novel antiangiogenic therapy target.
Area of Science:
- Cellular and Molecular Biology
- Oncology
- Vascular Biology
Background:
- Integrin alpha6beta4 plays a role in cellular adhesion and signaling.
- Angiogenesis, the formation of new blood vessels, is critical for tumor growth and metastasis.
Purpose of the Study:
- To investigate the role of integrin alpha6beta4 signaling in angiogenesis and tumor development.
- To determine if alpha6beta4 signaling is a viable target for antiangiogenic therapies.
Main Methods:
- Utilized a mouse model with a targeted deletion of the integrin beta4 subunit's signaling portion.
- Assessed angiogenesis using the Matrigel plug assay and a retinal neovascularization model.
- Analyzed tumor growth and vascularization in mutant and wild-type mice bearing cancer cell xenografts.
Main Results:
- Mice with deleted integrin beta4 signaling showed significantly reduced angiogenesis in response to bFGF and hypoxia.
- Alpha6beta4 signaling promoted endothelial cell migration and invasion, not proliferation or survival.
- Tumors in mutant mice were smaller and less vascularized compared to controls.
- Signaling pathways involving P-ERK and NF-kappaB were implicated in alpha6beta4-mediated endothelial cell responses.
Conclusions:
- Integrin alpha6beta4 signaling is essential for the invasive phase of pathological angiogenesis.
- Targeting alpha6beta4 signaling represents a novel strategy for antiangiogenic therapy.